Utilization and cost of anti-osteoporosis therapy among US Medicare beneficiaries

  title={Utilization and cost of anti-osteoporosis therapy among US Medicare beneficiaries},
  author={S. Jha and T. Bhattacharyya},
  journal={Archives of Osteoporosis},
  • S. Jha, T. Bhattacharyya
  • Published 2016
  • Medicine
  • Archives of Osteoporosis
  • SummaryThere is a strong impetus to prevent and treat osteoporosis to prevent fractures. $990 million dollars was spent on anti-osteoporosis drugs in 2013. As we shift our focus on primary prevention of fractures, providers are encouraged to find the most cost-effective anti-osteoporosis therapy for patients.PurposeOsteoporosis is a major global problem with osteoporotic fractures posing a potentially avoidable burden on healthcare resources. We studied the utilization and cost of anti… CONTINUE READING
    2 Citations
    Is It Time to Stop (or Pause) Vertebral Augmentation?
    • B. Clarke, S. Khosla
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2019
    • 3


    Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011
    • 217
    Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample.
    • 46
    • PDF
    Impact of a primary care physician workshop on osteoporosis medical practices
    • 15
    • PDF
    Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States.
    • 146
    • PDF
    Changing trends in osteoporosis care from specialty to primary care physicians
    • 6
    Recognition of osteoporosis by primary care physicians.
    • 94
    Multinational survey of osteoporotic fracture management
    • 71
    • PDF
    A reappraisal of generic bisphosphonates in osteoporosis
    • 58
    • PDF